Robust genomic approaches are now available to realize improvements in efficiencies and translational relevance of cancer risk assessments for drugs and chemicals. Mechanistic and pathway data generated via genomics provide opportunities to advance beyond historical reliance on apical endpoints of uncertain human relevance. Published research and regulatory evaluations include many examples for which genomic data have been applied to address cancer risk assessment as a health protection endpoint. The alignment of mature, robust, reproducible, and affordable technologies with increasing demands for reduced animal testing sets the stage for this important transition. We present our shared vision for change from leading scientists from academic, government, nonprofit, and industrial sectors and chemical and pharmaceutical safety applications. This call to action builds upon a 2017 workshop on "Advances and Roadblocks for Use of Genomics in Cancer Risk Assessment." The authors propose a path for implementation of innovative cancer risk assessment including incorporating genomic signatures to assess mechanistic relevance of carcinogenicity and enhanced use of genomics in benchmark dose and point of departure evaluations. Novel opportunities for the chemical and pharmaceutical sectors to combine expertise, resources, and objectives to achieve a common goal of improved human health protection are identified.

中文翻译：

---

跨部门呼吁通过使用基因组方法来改进致癌性风险评估。

现在可以使用强大的基因组方法来提高药物和化学品癌症风险评估的效率和转化相关性。通过基因组学生成的机制和途径数据提供了超越对人类相关性不确定的顶端终点的历史依赖的机会。已发表的研究和监管评估包括许多应用基因组数据将癌症风险评估作为健康保护终点的例子。成熟、稳健、可重复且负担得起的技术与减少动物试验的日益增长的需求相结合，为这一重要转变奠定了基础。我们提出了来自学术界、政府、非营利组织和工业部门以及化学和制药安全应用领域的顶尖科学家对变革的共同愿景。这一行动呼吁以 2017 年“基因组学在癌症风险评估中的应用进展和障碍”研讨会为基础。作者提出了一种实施创新癌症风险评估的途径，包括结合基因组特征来评估致癌性的机制相关性，并在基准剂量和出发点评估中加强基因组学的使用。化学和制药行业结合专业知识、资源和目标以实现改善人类健康保护的共同目标找到了新的机会。